Study uncovers hard-to-detect cancer mutations ​

New research, led by Li Ding, PhD, shows that current genome analysis approaches systematically miss detecting a certain type of complex mutation in cancer patients’ tumors. A significant percentage of these complex mutations are found in well-known cancer genes that could be targeted by existing drugs, potentially expanding the number of cancer patients who may benefit.